Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £250,000 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy aimed at treating relapsed/refractory acute myeloid leukemia in adults. This funding, raised through an allotment to CEO Vladislav Sandler, reflects investor confidence in the company’s progress and potential, as evidenced by the premium issue price of the shares.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies.
Average Trading Volume: 37,697
Technical Sentiment Signal: Sell
Current Market Cap: £7.71M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.